Biodextris

Biodextris keeps team together to provides analytical and process development services

The Website Store • March 31, 2016

LAVAL, QC, March 29, 2016 /CNW Telbec/ – Today Biodextris Inc. announces its suite of services and commitment to building a full service contract organization. The new contract research organization (CRO) provides analytical and process development services for vaccines and biologics products.


Formerly part of GSK-Vaccines principal North American R&D unit, the Biodextris team is comprised of key senior development scientists. Together they have developed dozens of products for early phase clinical trials conducted in the US, Canada and Europe.


When GSK ceased operations at the Laval facility in 2015, the team capitalized on the opportunity to offer their collective industry expertise as an independent service provider. Multinationals as well as small and medium enterprises use Biodextris’ analytical and process development services to advance their candidate vaccine and biologic products from the bench to the clinic.


“Our history within successful commercial organizations makes us an ideal partner to efficiently move products from candidate selection through clinical development”, commented Joseph Zimmermann, CEO of Biodextris. “The team’s passion, coupled with our capabilities and formal quality management systems, enable our vision to become a full service process development and manufacturing organization.”


An advantageous location in Canada’s premier life-sciences hub, allows Biodextris to provide cost competitive services to companies in the clinical phases of product development for complex vaccine and biologics products. Biodextris will participate in the World Vaccine Congress in Washington on March 29-31, 2016, to highlight opportunities for vaccine companies.


“Our Quality Management System is the backbone of everything we do”, said Christine Jacques, Analytical Services Director, “It is the reason large multinational pharmaceutical and innovative vaccine and biologics companies work with us.”


About Biodextris:

Biodextris Inc. is a Canadian contract research organization (CRO), providing a suite of analytical and process development services for vaccines and biologics products in the clinical stages of development. The company’s analytical and product development expertise, established facilities and formal quality management systems enable their vision to become a full service process development and manufacturing organization. www.biodextris.com


SOURCE biodextris

For further information:

Joseph Zimmermann, Biodextris Inc., joseph@biodextris.com

Biodextris - Bringing Innovation to Life

With Biodextris, your project is overseen by dedicated project managers with extensive hands-on experience, saving you time and enhancing your experience.


Learn more about us ➜

Leave A Comment

Search

Recent Posts

By Philippe Beland June 11, 2025
Biodextris Appoints Dr. Behzad Mahdavi as Executive Chairman & Chief Commercial Officer Who: Dr. Behzad Mahdavi, Ph.D., MBA, NACD.DC — a biopharma industry veteran with over 25 years of senior leadership experience in CDMO and CRO sectors, including roles at Lonza and Catalent. What: He has been appointed Executive Chairman and will additionally serve as Chief Commercial Officer at Biodextris. Why: Dr. Mahdavi will spearhead the company’s global commercial expansion, leveraging his expertise in commercial innovation and international market development About Biodextris: Headquartered in Laval (Montréal), Québec, Biodextris is a rising Contract Development & Manufacturing Organization (CDMO) specializing in biologics and vaccine development, rooted in the legacy of GSK’s biologics and supported by ArchiMed private equity. For full details, you can read the original PR Newswire article here: https://www.prnewswire.com/news-releases/biodextris-appoints-dr-behzad-mahdavi-as-executive-chairman-to-lead-global-commercial-expansion-302472664.html
December 17, 2024
Learn about the strategic partnership between Aramis Biotechnologies and Biodextris to advance vaccine and biologics development.
December 17, 2024
Clean Biologics acquires Biodextris—bringing together expertise in biologics manufacturing and accelerating growth in CDMO services.
Biodextris Inc. inaugure ses nouvelles installations en plein cœur de la Cité de la Biotech à Laval
By Philippe Beland October 9, 2024
Biodextris inaugure de nouvelles installations à Laval pour renforcer son expertise en développement biologique.
Biodextris Inc. inaugurates its new facilities in the heart of Laval's Biotech City
By Philippe Beland October 9, 2024
Biodextris inaugurates its new Laval facility in Biotech City, expanding its capabilities in biologics development and manufacturing.
cGMP biomanufacturing facility Laval
June 5, 2024
Discover Biodextris' new cGMP biomanufacturing and analytical facility. Check out our state-of-the-art capabilities.
More Posts

Share Posts